Regis Resources and Vault Minerals to Merge in $10.7B Gold Deal 
Supermicro Forecasts Strong Q4 Revenue Growth as AI Server Demand Surges 
Middle East Conflict Impacts Australia and New Zealand Businesses 
Lufthansa Q1 Loss Narrows as Strong Summer Travel Demand Boosts Outlook 
Strategy Hints at Bitcoin Sales to Cover Dividends After Massive Q1 Loss 
Berkshire Hathaway Meeting Sees Shift as Greg Abel Steps Into Leadership Spotlight 
AMD Q1 Earnings Surge on AI Demand, Stock Jumps After Strong Guidance 
Rivian Hints at New R2 Variants as Production Ramps Up Ahead of 2027 Launch 
Agentic AI Boom to Drive Massive Growth in CPU Market, UBS Says 
Strategy Reports Q1 Loss as Bitcoin Holdings Trigger $14.46 Billion Unrealized Hit 
Hugo Boss Beats Q1 Profit Expectations Despite Market Headwinds 
Palantir Reports Record Growth, Raises 2026 Revenue Outlook Above Expectations 
Volvo Car Sales Drop 10% in Early 2026 Despite Growth in Electric Vehicles 
Novo Nordisk Raises 2026 Outlook on Strong Wegovy Demand 
BHP Attracts AI-Focused Investors as Copper Demand Surges 
GameStop Proposes $56 Billion eBay Acquisition in Bold Strategic Move 
CAMBRIDGE, Mass., May 07, 2018 -- Mersana Therapeutics, Inc. (NASDAQ:MRSN), a clinical-stage biopharmaceutical company focused on discovering and developing a pipeline of antibody drug conjugates (ADCs) based on its Dolaflexin® and other proprietary platforms, today announced that it will host a conference call and webcast on Monday, May 14, 2018, at 5:00 p.m. ET to report financial results for the first quarter 2018 and provide business updates.
To access the call, please dial 877-303-9226 (domestic) or 409-981-0870 (international) and provide the Conference ID 7589367. A live webcast of the presentation will be available on the Investors & Media section of the Mersana website at www.mersana.com.
About Mersana Therapeutics
Mersana Therapeutics is a clinical-stage biopharmaceutical company using its differentiated and proprietary ADC platforms to develop highly targeted drugs with increased tolerability and expanded opportunities to deliver meaningful clinical benefit to patients. Mersana’s product candidate XMT-1522 is in Phase 1 clinical trials in patients with advanced tumors expressing HER2, including breast cancer, non-small-cell-lung-cancer (NSCLC) and gastric cancer patients. The Company’s second product candidate, XMT-1536, is in Phase 1 clinical trials in patients with tumors expressing NaPi2b, including ovarian cancer, NSCLC and other cancers. In addition, multiple partners are using Mersana’s platform to advance their ADC pipelines.
Media Contact
Paul Kidwell
[email protected]
617-680-1088
Investor Contact
Stern Investor Relations, Inc.
Christina Tartaglia
[email protected]
212-362-1200
